论文部分内容阅读
目的 探讨应用免疫散射比浊法测定血浆D 二聚体 (D dimer,DD)与缺血性心脑血管疾病的关系。方法 采用近年应用于临床的免疫散射比浊法检测 6 3例缺血性心脑血管病患者的D 二聚体水平。结果 30例冠心病人及 33例脑梗死病人的血浆D 二聚体含量分别为 (36 8 77± 2 6 3 86 )ng/ml和 (6 4 4 6 4± 31 2 93)ng/ml,明显高于对照组 (93 5± 6 3 94ng/ml)。其中脑梗死病人D 二聚体含量增高更为显著 ,考虑与两种疾病的发病机制、病理生理有关。结论 用免疫散射比浊法定量分析检测 ,能客观地反映体内血栓形成及继发纤溶的程度 ,有待收集更多的临床数据 ,获取更有参考价值的资料 ,作为该类疾病的诊断、预后、溶栓治疗动态监测的重要指标
Objective To investigate the relationship between plasma D dimer (D dimer, DD) and ischemic cardiovascular and cerebrovascular diseases by immune nephelometry. Methods D-dimer levels in 63 patients with ischemic cardiovascular and cerebrovascular diseases were detected by immune nephelometry in recent years. Results The plasma levels of D dimer in 30 patients with coronary heart disease and 33 patients with cerebral infarction were (36 8 77 ± 26 366) / ml and (6444 ± 31 2 93) ng / ml, respectively, Significantly higher than the control group (93 5 ± 6 3 94ng / ml). In which cerebral infarction patients D dimer increased more significantly, consider the pathogenesis of both diseases, pathophysiology. Conclusion Quantitative immunoassay with turbidimetric method can objectively reflect the degree of thrombosis and secondary fibrinolysis in vivo. More clinical data needs to be collected to obtain more reference data as a diagnostic and prognostic factor for this type of disease Thrombolytic therapy dynamic monitoring of important indicators